Despite commonly used practices, usage of different types of pharyngeal packing did not affect incidence of PONV and throat pain, nor did usage of no packing.

Purpose Idiopathic facial palsy is called as Bell's palsy and reports showed that facial paralysis increased during COVID-19 pandemic period. There are many reports about the relationship between COVID-19 and facial paralysis but there is no prospective study. SARS-CoV-2 IgG and IgM antibodies increase in COVID-19. Our purpose is to investigate SARS-CoV-2 IgG + IgM antibody in the Bell's palsy. Methods Prospective cross-sectional study was planned. Patients with acute peripheral facial paralysis with no reason and diagnosed as Bell's palsy was included in the study. In order to investigate SARS-CoV-2 in the etiologies of these patients, SARS-CoV-2 IgM + IgG (total) test was studied. SARS-CoV-2 IgG + IgM was measured by using the ADVIA Centaur® test kit. Test reports result in index values and as nonreactive or reactive. The results were analyzed. Results Forty-one patients were included in the study. The average age of the patients was 41,7. 17 (41,4%) were female and 24 (58,6%) were male. 21 patients had left-sided; 20 had right-sided paralysis. SARS-CoV-2 IgG + IgM values were measured two times of the patients. First control was in the first week of facial paralysis, 10 (24,3%) positivity was found. The average index of the positive patients were 6,74 (min.1,39–max.10) in the first control and 9,585 in the second control (min.8,7–max. 10). Conclusion We found that the SARS-CoV-2 IgM + IgG antibody test was positive in 24.3% of the patients with Bell's palsy. The results are higher than the seroprevalence studies conducted in asymptomatic individuals. Facial paralysis could be the only symptom of COVID-19 but further studies must be done.

Background As the SARS-CoV-2 virus made a pandemic all over the world, its transmission routes became significant. Transmission from human to human is known, but other possible routes are not determined well. Aims This study aimed to reveal the presence of SARS-CoV-2 virus in sweat. Methods This prospective study was conducted in a tertiary care education and training hospital. Fifty patients were included in this study. Skin disinfection was done with an alcohol-based solution. Swabs for RT-PCR (real-time reverse transcriptase polymerase chain reaction) were taken from forehead and axilla skin after sweating patients for 30 min. After collection of sweat, swabs were placed into 2 ml of sterile viral transport medium, then transported quickly to the microbiology laboratory. Results No SARS-CoV-2 virus was detected in RT-PCR of forehead and axilla swabs. Conclusion This study showed that there is no transmission of SARS-CoV-2 virus via sweat. However, general precautions must be taken while doing interventional procedures.

Background COVID-19 is a new disease caused by the SARS-CoV-2 virus. The olfactory dysfunction linked to COVID-19 is not associated with rhinorrhea but there is no objective evaluation. Aims To evaluate nasal mucosal secretion objectively in COVID-19 patients with anosmia. Methods Fifty-two COVID-19 patients with anosmia and 51 healthy individuals included. Anosmia was diagnosed by subjective questionnaires. Nasal Schirmer test was done to the left and the right nasal cavity separately. Results All patients had anosmia and 82.6% had gustatory dysfunction. In group 1, the mean of the nasal Schirmer test results in the right cavity was 12.4 mm, 12.01 mm in the left nasal cavity. The median wetting distance (right plus left divided by two) was calculated 12.21 mm. In group 2, the mean of the nasal Schirmer test results in the right cavity was 12.1 mm, 11.8 mm in the left nasal cavity. The median wetting distance (right plus left divided by two) was calculated11.97 mm. There was no difference between the two groups in terms of nasal schirmer. Conclusion Olfactory dysfunction and gustatory dysfunction are the two of the unknown for this disease. We evaluated the nasal mucosa secretions in COVID-19 patients with anosmia objectively to evaluate if there is inflammation in the nasal mucosa. We found no difference between healthy individuals. According to our study, SARS-CoV-2 causes anosmia without causing nasal mucosal inflammation. Invasion of the olfactory bulb and central nervous system by SARS-CoV-2 may lead to anosmia in COVID-19, which may cause olfactory dysfunction.

Objective: To evaluate the presence of SARS-CoV-2 virus in the cerumen of patients with COVID-19. Methods: A prospective study was conducted in a tertiary care pandemic hospital. Sixty COVID-19 patients with cerumen in their external auditory canals were included in the study. Swabs were taken from the external auditory canal of the patients by an experienced otolaryngologist with the test swab. Sampling was done by rotating the sample swab 360° 10 times in each external auditory canal for a total of 20 times. After collection, swabs were placed into 2 mL of the sterile viral transport medium (various manufacturers), then transported and tested as soon as possible after collection. Results: SARS-CoV-2 was not detected in the cerumen polymerase chain reaction (PCR) samples of any of the 60 patients with positive nasopharyngeal/oropharyngeal swabs. Conclusion: Cerumen cleaning is one of the most common procedures performed by otolaryngologists, and care should be taken during the procedure or due to the possibility of infection from the resulting contaminants. The cerumen contains the secretions of the glands in the external auditory canal and may contain certain pathogens that are actively found in the body. The presence of hepatitis B virus in the cerumen was examined and isolated in the cerumen. In our study, the presence of SARS-CoV-2 virus in the cerumen was evaluated in SARS-CoV-2 PCR-positive patients. SARS-CoV-2 virus was not detected in the cerumen samples of any of the patients.